Breast Cancer Clinical Trial
Official title:
Description of the Analgesia Obtained With the Anesthesiological Protocols Currently Used in Breast Surgery
| Verified date | March 2020 |
| Source | Careggi Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study aims to describe the pain-relieving effect obtained with the current post-surgery pain control methods used in breast surgery by measuring the painful sensation and the consumption of opioids in the first 24 post-surgery hours. It also aims to describe the appearance of any complications such as post-surgery nausea and vomiting. Current anesthesia involves the combined use of intravenous painkillers and anti-inflammatory drugs such as acetaminophen, ketorolac, tramadol or morphine (the latter via PCA system = patient-controlled analgesia) or for local administration at the surgical site level ( local anesthetics). It is also proposed to describe the intensity and interference of pain in daily activities
| Status | Completed |
| Enrollment | 200 |
| Est. completion date | July 31, 2018 |
| Est. primary completion date | July 31, 2018 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Female gender - Age> 18 years; - Patients in ASA class <4; - Planned mastectomy surgery, simple mastectomy with immediate reconstruction, mastectomy with sentinel-lymph node biopsy, modified radical mastectomy (unilateral or bilateral); - Absence of allergies or hypersensitivity reported and / or documented to drugs used routinely for post-operative analgesia; - Absence of inflammatory changes at the surgical site level; - Presence of the patient's informed consent to the processing of personal data; Exclusion Criteria: - Known alterations of coagulation; - Known cardiac arrhythmias (atrial sinus block I, II, III type, atrioventricular block I, II and III type); - Documented renal failure (patient undergoing renal replacement therapy, or creatininemia = 2 mg / dl); - Severe hepatic insufficiency (Child-Plugh class III and IV); Seizure states (absences, seizures of large and / or small epileptic disease); - Respiratory failure (PaO2 = 60mmHg PaCO2= 50mmHg); |
| Country | Name | City | State |
|---|---|---|---|
| Italy | Azienda Ospedaliero Universitaria Careggi | Florence |
| Lead Sponsor | Collaborator |
|---|---|
| Careggi Hospital |
Italy,
AIRTUM Working Group. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev. 2013 Jul-Oct;37(4-5 Suppl 1):1-152. English, Italian. — View Citation
Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain. 2011 Jul;12(7):725-46. doi: 10.1016/j.jpain.2010.12.005. Epub 2011 Mar 24. Review. — View Citation
Aufforth R, Jain J, Morreale J, Baumgarten R, Falk J, Wesen C. Paravertebral blocks in breast cancer surgery: is there a difference in postoperative pain, nausea, and vomiting? Ann Surg Oncol. 2012 Feb;19(2):548-52. doi: 10.1245/s10434-011-1899-5. Epub 2011 Jul 16. — View Citation
Bashandy GM, Abbas DN. Pectoral nerves I and II blocks in multimodal analgesia for breast cancer surgery: a randomized clinical trial. Reg Anesth Pain Med. 2015 Jan-Feb;40(1):68-74. doi: 10.1097/AAP.0000000000000163. — View Citation
Blanco R, Fajardo M, Parras Maldonado T. Ultrasound description of Pecs II (modified Pecs I): a novel approach to breast surgery. Rev Esp Anestesiol Reanim. 2012 Nov;59(9):470-5. doi: 10.1016/j.redar.2012.07.003. Epub 2012 Aug 29. — View Citation
Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia. 2013 Nov;68(11):1107-13. doi: 10.1111/anae.12344. Epub 2013 Aug 7. — View Citation
Blanco R. The 'pecs block': a novel technique for providing analgesia after breast surgery. Anaesthesia. 2011 Sep;66(9):847-8. doi: 10.1111/j.1365-2044.2011.06838.x. — View Citation
Bouzinac A, Tournier JJ, Merouani M, Delbos A. [Sensory blockade and efficiency of the "pec block 2" for postoperative analgesia after breast cancer surgery]. J Gynecol Obstet Biol Reprod (Paris). 2015 Jan;44(1):98-9. doi: 10.1016/j.jgyn.2014.09.004. Epub 2014 Oct 1. French. — View Citation
Caraceni A, Mendoza TR, Mencaglia E, Baratella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de Conno F, Cleeland CS. A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain. 1996 Apr;65(1):87-92. — View Citation
Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006 Oct;105(4):660-4. — View Citation
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027. Epub 2013 Feb 26. — View Citation
Gewandter JS, Dworkin RH, Turk DC, Farrar JT, Fillingim RB, Gilron I, Markman JD, Oaklander AL, Polydefkis MJ, Raja SN, Robinson JP, Woolf CJ, Ziegler D, Ashburn MA, Burke LB, Cowan P, George SZ, Goli V, Graff OX, Iyengar S, Jay GW, Katz J, Kehlet H, Kitt RA, Kopecky EA, Malamut R, McDermott MP, Palmer P, Rappaport BA, Rauschkolb C, Steigerwald I, Tobias J, Walco GA. Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain. 2015 Jul;156(7):1184-97. doi: 10.1097/j.pain.0000000000000191. Review. — View Citation
Kairaluoma PM, Bachmann MS, Korpinen AK, Rosenberg PH, Pere PJ. Single-injection paravertebral block before general anesthesia enhances analgesia after breast cancer surgery with and without associated lymph node biopsy. Anesth Analg. 2004 Dec;99(6):1837-43, table of contents. — View Citation
Katz J, Poleshuck EL, Andrus CH, Hogan LA, Jung BF, Kulick DI, Dworkin RH. Risk factors for acute pain and its persistence following breast cancer surgery. Pain. 2005 Dec 15;119(1-3):16-25. Epub 2005 Nov 17. — View Citation
Langford R, Brown I, Vickery J, Mitchell K, Pritchard C, Creanor S. Study protocol for a double blind, randomised, placebo-controlled trial of continuous subpectoral local anaesthetic infusion for pain and shoulder function following mastectomy: SUB-pectoral Local anaesthetic Infusion following MastEctomy (SUBLIME) study. BMJ Open. 2014 Sep 30;4(9):e006318. doi: 10.1136/bmjopen-2014-006318. — View Citation
Lynch EP, Welch KJ, Carabuena JM, Eberlein TJ. Thoracic epidural anesthesia improves outcome after breast surgery. Ann Surg. 1995 Nov;222(5):663-9. — View Citation
Schnabel A, Reichl SU, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of paravertebral blocks in breast surgery: a meta-analysis of randomized controlled trials. Br J Anaesth. 2010 Dec;105(6):842-52. doi: 10.1093/bja/aeq265. Epub 2010 Oct 14. Review. Erratum in: Br J Anaesth. 2013 Sep;111(3):522. — View Citation
Sopena-Zubiria LA, Fernández-Meré LA, Valdés Arias C, Muñoz González F, Sánchez Asheras J, Ibáñez Ernández C. [Thoracic paravertebral block compared to thoracic paravertebral block plus pectoral nerve block in reconstructive breast surgery]. Rev Esp Anestesiol Reanim. 2012 Jan;59(1):12-7. doi: 10.1016/j.redar.2011.10.001. Epub 2012 Mar 14. Spanish. — View Citation
* Note: There are 18 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Assessment of the change of level of anesthesia | Describing the level of analgesia obtained in the first 24 hours post-operative in patients undergoing simple mastectomy, mastectomy with immediate reconstruction with expander or retropectoral prosthesis, mastectomy with sentinel node biopsy and radical mastectomy modified with the anesthesiological protocols used routinariamentally. Analgesia will be evaluated every 6 hours and for the first 24 post-operative hours (at 0, 6, 12, 18, 24 hours from the end of the surgical intervention) through the NRS (Numerical Rating Scale). The Numerical Rating Scale is a pain sensation rating scale at points where the patient chooses a value ranging from 0 (no pain) to 10 (maximum pain). From 1 to 3 it is considered mild pain, from 4-7 moderate, from 8-10 severe. |
Up to 24 hours after surgery | |
| Secondary | Describing the total amount of morphine used in the first 24 post-operative hours. | The total amount of morphine used will be expressed in milligrams of morphine used by the patient in the first 24 hours post-operative normalized per kilogram of body weight (mg / kg). | 24 hours after surgery | |
| Secondary | Describing the incidence of PONV (Postoperative Nausea and Vomiting). | The incidence of PONV, measured at 0, 6, 12, 18 and 24 hours will be expressed in terms of percentage. | 24 hours after surgery | |
| Secondary | Describing of change in severity of PONV (Postoperative Nausea and Vomiting). | The incidence of PONV, measured at 0, 6, 12, 18 and 24 hours will be expressed in terms of percentage. The severity of PONV will be expressed according to the following evaluation scheme: absence of nausea = 0, mild nausea = 1, moderate = 2, severe nausea or vomiting = 3 | 24 hours after surgery | |
| Secondary | Description of the change of the intensity of pain on daily activities reported by patients undergoing breast surgery. | The painful sensation is assessed by six questions on the quality of pain experienced in the previous 24 hours; for each question, an answer corresponding to a numerical value from 0 (no pain) to 10 (maximum) according to the Numerical Rating Scale (NRS) is requested and recorded. In addition, the percentage of relief provided by analgesic drugs, possibly taken, is investigated by administering a question and recording a percentage value, from 0% (minimum) to 100% (maximum), referring to the percentage sensation of pain relief. A second question is requested related to the type of drug possibly taken. At the end of the questionnaire, an overall score is calculated regarding the questions on the intensity of pain (0-40, 0-10 points for each answer to questions 3 to 6). A score of 0 (no pain) to 10 (maximum pain) is referred to the percentage of relief given by the analgesics corresponding to the value given in percentage / 10. | 3 months after surgery | |
| Secondary | Description of the change of the interference of pain on daily activities reported by patients undergoing breast surgery. | The interference of pain includes the evaluation of 7 fields referring to which patients can express for each field, according to a numerical scale from 0 (minimum) to 10 (maximum), how much pain interferes. The numerical scale from 0-10 allows to record a response that varies between 0 = no interference in the activity, and 10 = completely interferes with the activity. This scale has been validated according to psychometric criteria. At the end of the questionnaire, an overall score is calculated regarding the questions on the intensity of pain (0-40, 0-10 points for each answer to questions 3 to 6). A score from 0-10 refers to the percentage of relief given by the analgesics corresponding to the value given as a percentage / 10. An overall score is calculated from 0 (no interference) to 70 (maximum interference), from 0 to 10 for each of the seven fields. | 3 months after surgery | |
| Secondary | Description of the change of the incidence and impact on daily activities of the pain reported by patients undergoing breast surgery. | The incidence on daily pain activities will be assessed 3 months after surgery through the Brief Pain Inventory (BPI ) scale in the Italian validated version. The Brief Pain Inventory questionnaire evaluates the multidimensional experience of pain through two domains: the intensity of pain and the interference of pain (see the following outcome) in daily activities.An overall final score is calculated from 0 (minimum) to 120 (maximum) corresponding to the multidimensional experience of pain, obtained from outcomes 5 and 6 | 3 months after surgery |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |